← Back to Clinical Trials
Recruiting Phase 2 NCT06189820
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Trial Parameters
Condition Pulmonary Fibrosis
Sponsor Erasme University Hospital
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 70
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-03-09
Completion 2027-03-09
All Conditions
Interventions
FAPI PET/CT
Brief Summary
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
Eligibility Criteria
Inclusion Criteria: * Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines Exclusion Criteria: * Pregnant or nursing patients * Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study. * Patients with an active lung neoplasm or any active neoplasm for blood samples
Related Trials
NCT06189820
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
View Trial →
NCT03535545
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary F
View Trial →
NCT00258570
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
View Trial →